{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T21:14:12Z","timestamp":1788297252001,"version":"build-2803163510"},"reference-count":157,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T00:00:00Z","timestamp":1659484800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T00:00:00Z","timestamp":1659484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hormones"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s42000-022-00391-w","type":"journal-article","created":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T11:02:44Z","timestamp":1659524564000},"page":"573-589","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Detangling the interrelations between MAFLD, insulin resistance, and key hormones"],"prefix":"10.1007","volume":"21","author":[{"given":"Shreya C.","family":"Pal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Eslam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahum","family":"Mendez-Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,3]]},"reference":[{"issue":"S1","key":"391_CR1","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","volume":"62","author":"CD Byrne","year":"2015","unstructured":"Byrne CD, Targher G (2015) NAFLD: a multisystem disease. J Hepatol 62(S1):S47-64. https:\/\/doi.org\/10.1016\/j.jhep.2014.12.012","journal-title":"J Hepatol"},{"issue":"1","key":"391_CR2","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/hep.29466","volume":"67","author":"C Estes","year":"2018","unstructured":"Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ (2018) Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 67(1):123\u2013133","journal-title":"Hepatology"},{"issue":"10290","key":"391_CR3","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"Powell EE, Wong VWS, Rinella M (2021) Non-alcoholic fatty liver disease. Lancet 397(10290):2212\u20132224. https:\/\/doi.org\/10.1016\/S0140-6736(20)32511-3","journal-title":"Lancet"},{"issue":"4","key":"391_CR4","doi-asserted-by":"publisher","first-page":"543","DOI":"10.2147\/DMSO.S146339","volume":"56","author":"R Sarwar","year":"2018","unstructured":"Sarwar R, Pierce N, Koppe S (2018) Obesity and nonalcoholic fatty liver disease. Diabetes, Metab Syndrome Obes: Targets Ther 56(4):543\u2013552. https:\/\/doi.org\/10.2147\/DMSO.S146339","journal-title":"Diabetes, Metab Syndrome Obes: Targets Ther"},{"issue":"3","key":"391_CR5","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","volume":"70","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM (2019) Non-alcoholic fatty liver disease \u2013 a global public health perspective. J Hepatol 70(3):531\u2013544. https:\/\/doi.org\/10.1016\/j.jhep.2018.10.033","journal-title":"J Hepatol"},{"issue":"3","key":"391_CR6","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/j.1365-2036.2011.04724","volume":"34","author":"G Vernon","year":"2011","unstructured":"Vernon G, Baranova A, Younossi ZM (2011) Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 34(3):274\u2013285. https:\/\/doi.org\/10.1111\/j.1365-2036.2011.04724","journal-title":"Aliment Pharmacol Ther"},{"key":"391_CR7","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/ncpgasthep0879","volume":"4","author":"C Nugent","year":"2007","unstructured":"Nugent C, Younossi Z (2007) Evaluation and management of obesity-related nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 4:432\u2013441. https:\/\/doi.org\/10.1038\/ncpgasthep0879","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"7","key":"391_CR8","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s00392-020-01709-7","volume":"110","author":"P Kasper","year":"2021","unstructured":"Kasper P, Martin A, Lang S, K\u00fctting F, Goeser T, Demir M et al (2021) NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol 110(7):921\u2013937. https:\/\/doi.org\/10.1007\/s00392-020-01709-7","journal-title":"Clin Res Cardiol"},{"issue":"9","key":"391_CR9","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","volume":"69","author":"G Targher","year":"2020","unstructured":"Targher G, Byrne CD, Tilg H (2020) NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut 69(9):1691\u20131705. https:\/\/doi.org\/10.1136\/gutjnl-2020-320622","journal-title":"Gut"},{"issue":"1","key":"391_CR10","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1210\/clinem\/dgab641","volume":"107","author":"Y Liang","year":"2022","unstructured":"Liang Y, Chen H, Liu Y, Hou X, Wei L, Bao Y et al (2022) Association of MAFLD with diabetes, chronic kidney disease, and cardiovascular disease: a 4.6-year cohort study in China. J Clin Endocrinol Metab. 107(1):88\u201397. https:\/\/doi.org\/10.1210\/clinem\/dgab641","journal-title":"J Clin Endocrinol Metab."},{"issue":"9","key":"391_CR11","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S2468-1253(21)00132-1","volume":"6","author":"M Eslam","year":"2021","unstructured":"Eslam M, Ahmed A, Despr\u00e9s J-P, Jha V, Halford JCG, Wei Chieh JT et al (2021) Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases. Lancet Gastroenterol Hepatol 6(9):743\u2013753. https:\/\/doi.org\/10.1016\/S2468-1253(21)00132-1","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"391_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2019.154005","volume":"101","author":"N Perakakis","year":"2019","unstructured":"Perakakis N, Polyzos SA, Yazdani A, Sala-Vila A, Kountouras J, Anastasilakis AD et al (2019) Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: a proof of concept study. Metabolism 101:154005. https:\/\/doi.org\/10.1016\/j.metabol.2019.154005","journal-title":"Metabolism"},{"issue":"6","key":"391_CR13","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.3390\/diagnostics11061078","volume":"11","author":"N Katsiki","year":"2019","unstructured":"Katsiki N, Gastaldelli A, Mikhailidis DP (2019) Predictive models with the use of omics and supervised machine learning to diagnose non-alcoholic fatty liver disease: a \u201cnon-invasive alternative\u201d to liver biopsy? Metabolism 11(6):1078. https:\/\/doi.org\/10.3390\/diagnostics11061078","journal-title":"Metabolism"},{"issue":"8","key":"391_CR14","doi-asserted-by":"publisher","first-page":"3830","DOI":"10.21037\/qims-20-1151","volume":"11","author":"J Olveres","year":"2021","unstructured":"Olveres J, Gonz\u00e1lez G, Torres F, Moreno-Tagle JC, Carbajal-Degante E, Valencia-Rodr\u00edguez A et al (2021) What is new in computer vision and artificial intelligence in medical image analysis applications. Quant Imaging Med Surg 11(8):3830\u20133853. https:\/\/doi.org\/10.21037\/qims-20-1151","journal-title":"Quant Imaging Med Surg"},{"key":"391_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/17562848211062807","volume":"14","author":"P Decharatanachart","year":"2021","unstructured":"Decharatanachart P, Chaiteerakij R, Tiyarattanachai T, Treeprasertsuk S (2021) Application of artificial intelligence in non-alcoholic fatty liver disease and liver fibrosis: a systematic review and meta-analysis Pakanat. Therap Adv Gastroenterol 14:1\u201317. https:\/\/doi.org\/10.1177\/17562848211062807","journal-title":"Therap Adv Gastroenterol"},{"issue":"6","key":"391_CR16","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","volume":"64","author":"G Marchesini","year":"2016","unstructured":"Marchesini G, Day CP, Dufour JF, Canbay A, Nobili V, Ratziu V et al (2016) EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 64(6):1388\u20131402. https:\/\/doi.org\/10.1016\/j.jhep.2015.11.004","journal-title":"J Hepatol"},{"issue":"1","key":"391_CR17","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M et al (2020) A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol 73(1):202\u2013209. https:\/\/doi.org\/10.1016\/j.jhep.2020.03.039","journal-title":"J Hepatol"},{"issue":"10","key":"391_CR18","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/S2468-1253(21)00183-7","volume":"6","author":"M Eslam","year":"2021","unstructured":"Eslam M, Alkhouri N, Vajro P, Baumann U, Weiss R, Socha P et al (2021) Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement. Lancet Gastroenterol Hepatol 6(10):864\u2013873. https:\/\/doi.org\/10.1016\/S2468-1253(21)00183-7","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"391_CR19","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1002\/hep.31420","volume":"73","author":"ZM Younossi","year":"2021","unstructured":"Younossi ZM, Rinella ME, Sanyal AJ, Harrison SA, Brunt EM, Goodman Z et al (2021) From NAFLD to MAFLD: implications of a premature change in terminology. Hepatology 73(3):1194\u20131198. https:\/\/doi.org\/10.1002\/hep.31420","journal-title":"Hepatology"},{"key":"391_CR20","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1161\/ATV.0000000000000153","volume":"42","author":"PB Duell","year":"2022","unstructured":"Duell PB, Welty FK, Miller M, Chait A, Hammond G, Ahmad Z et al (2022) Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol 42:e168\u2013e185. https:\/\/doi.org\/10.1161\/ATV.0000000000000153","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"391_CR21","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s12072-020-10094-2","volume":"14","author":"M Eslam","year":"2020","unstructured":"Eslam M, Sarin SK, Wai V, Wong S, Gao J, Takumi F et al (2020) The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hep Intl 14:889\u2013919. https:\/\/doi.org\/10.1007\/s12072-020-10094-2","journal-title":"Hep Intl"},{"issue":"1","key":"391_CR22","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S2468-1253(20)30294-6","volume":"6","author":"G Shiha","year":"2022","unstructured":"Shiha G, Korenjak M, Eskridge W, Casanovas T, Velez-Moller P, H\u00f6gstr\u00f6m S et al (2022) Redefining fatty liver disease: an international patient perspective. Lancet Gastroenterol Hepatol 6(1):73\u201379. https:\/\/doi.org\/10.1016\/S2468-1253(20)30294-6","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"11","key":"391_CR23","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1111\/hepr.13685.25","volume":"51","author":"T Tsutsumi","year":"2021","unstructured":"Tsutsumi T, Eslam M, Kawaguchi T, Yamamura S, Kawaguchi A, Nakano D et al (2021) MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: generalized estimating equation approach. Hepatol Res 51(11):1115\u20131128. https:\/\/doi.org\/10.1111\/hepr.13685.25","journal-title":"Hepatol Res"},{"issue":"12","key":"391_CR24","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1111\/liv.14675","volume":"40","author":"S Yamamura","year":"2020","unstructured":"Yamamura S, Eslam M, Kawaguchi T, Tsutsumi T, Nakano D, Yoshinaga S et al (2020) MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. Liver Int 40(12):3018\u20133030. https:\/\/doi.org\/10.1111\/liv.14675","journal-title":"Liver Int"},{"issue":"2","key":"391_CR25","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/hep.32131","volume":"75","author":"J Alharthi","year":"2022","unstructured":"Alharthi J, Gastaldelli A, Cua IH, Ghazinian H, Eslam M (2022) Metabolic dysfunction-associated fatty liver disease. Curr Opin Gastroenterol 75(2):419\u2013429. https:\/\/doi.org\/10.1002\/hep.32131","journal-title":"Curr Opin Gastroenterol"},{"issue":"15","key":"391_CR26","doi-asserted-by":"publisher","first-page":"922","DOI":"10.12998\/wjcc.v6.i15.922","volume":"6","author":"N M\u00e9ndez-S\u00e1nchez","year":"2018","unstructured":"M\u00e9ndez-S\u00e1nchez N, Zamarripa-Dorsey F, Panduro A, Pur\u00f3n-Gonz\u00e1lez E, Coronado-Alejandro EU, Cortez-Hern\u00e1ndez CA et al (2018) Current trends of liver cirrhosis in Mexico: similitudes and differences with other world regions. World J Clin Cases 6(15):922\u2013930. https:\/\/doi.org\/10.12998\/wjcc.v6.i15.922","journal-title":"World J Clin Cases"},{"issue":"1","key":"391_CR27","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M (2016) Global epidemiology of nonalcoholic fatty liver disease\u2014meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64(1):73\u201384. https:\/\/doi.org\/10.1002\/hep.28431","journal-title":"Hepatology"},{"issue":"7","key":"391_CR28","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.tips.2019.05.002","volume":"40","author":"M Eslam","year":"2019","unstructured":"Eslam M, George J (2019) Genetic insights for drug development in NAFLD. Trends Pharmacol Sci 40(7):506\u2013516. https:\/\/doi.org\/10.1016\/j.tips.2019.05.002","journal-title":"Trends Pharmacol Sci"},{"issue":"6","key":"391_CR29","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.tig.2020.03.003","volume":"36","author":"A Bayoumi","year":"2020","unstructured":"Bayoumi A, Gr\u00f8nb\u00e6k H, George J, Eslam M (2020) The epigenetic drug discovery landscape for metabolic-associated fatty liver disease. Trends Genet 36(6):429\u2013441. https:\/\/doi.org\/10.1016\/j.tig.2020.03.003","journal-title":"Trends Genet"},{"issue":"9","key":"391_CR30","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1111\/liv.13397","volume":"37","author":"S Petta","year":"2017","unstructured":"Petta S, Eslam M, Valenti L, Bugianesi E, Barbara M, Camm\u00e0 C et al (2017) Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: an age-dependent risk profiling study. Liver Int 37(9):1389\u20131396. https:\/\/doi.org\/10.1111\/liv.13397","journal-title":"Liver Int"},{"issue":"1","key":"391_CR31","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S2468-1253(20)30340-X","volume":"6","author":"N Mendez-Sanchez","year":"2021","unstructured":"Mendez-Sanchez N, Arrese M, Gadano A, Oliveira CP, Fassio E, Arab JP et al (2021) The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease. Lancet Gastroenterol Hepatol 6(1):65\u201372. https:\/\/doi.org\/10.1016\/S2468-1253(20)30340-X","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"391_CR32","doi-asserted-by":"publisher","first-page":"8591","DOI":"10.3390\/ijms15058591","volume":"15","author":"W Peverill","year":"2014","unstructured":"Peverill W, Powell LW, Skoien R (2014) Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation. Int J Mol Sci 15(5):8591\u20138638. https:\/\/doi.org\/10.3390\/ijms15058591","journal-title":"Int J Mol Sci"},{"issue":"8","key":"391_CR33","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","volume":"65","author":"E Buzzetti","year":"2016","unstructured":"Buzzetti E, Pinzani M, Tsochatzis EA (2016) The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 65(8):1038\u20131048. https:\/\/doi.org\/10.1016\/j.metabol.2015.12.012","journal-title":"Metabolism"},{"issue":"1","key":"391_CR34","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41575-019-0212-0","volume":"17","author":"M Eslam","year":"2019","unstructured":"Eslam M, George J (2019) Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology. Nat Rev Gastroenterol Hepatol 17(1):40\u201352. https:\/\/doi.org\/10.1038\/s41575-019-0212-0","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"8","key":"391_CR35","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/S2468-1253(20)30090-X","volume":"5","author":"M Eslam","year":"2020","unstructured":"Eslam M, Fan JG, Mendez-Sanchez N (2020) Non-alcoholic fatty liver disease in non-obese individuals: the impact of metabolic health. Lancet Gastroenterol Hepatol 5(8):713\u2013715. https:\/\/doi.org\/10.1016\/S2468-1253(20)30090-X","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"391_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1001324","volume":"7","author":"EK Speliotes","year":"2011","unstructured":"Speliotes EK, Yerges-Armstrong LM, Wu J, Hernaez R, Kim LJ, Palmer CD et al (2011) Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 7(3):e1001324. https:\/\/doi.org\/10.1371\/journal.pgen.1001324","journal-title":"PLoS Genet"},{"issue":"11","key":"391_CR37","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/nrgastro.2013","volume":"10","author":"QM Anstee","year":"2013","unstructured":"Anstee QM, Day CP (2013) The genetics of NAFLD. Nat Rev Gastroenterol Hepatol 10(11):645\u2013655. https:\/\/doi.org\/10.1038\/nrgastro.2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"11","key":"391_CR38","doi-asserted-by":"publisher","first-page":"4130","DOI":"10.1172\/JCI65179","volume":"122","author":"JZ Li","year":"2012","unstructured":"Li JZ, Huang Y, Karaman R, Ivanova PT, Brown HA, Roddy T et al (2012) Chronic overexpression of PNPLA3 I148M in mouse liver causes hepatic steatosis. J Clin Invest 122(11):4130\u20134144. https:\/\/doi.org\/10.1172\/JCI65179","journal-title":"J Clin Invest"},{"issue":"3","key":"391_CR39","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.jhep.2021.10.016","volume":"76","author":"B Guo","year":"2022","unstructured":"Guo B, Guo Y, Nima Q, Feng Y, Wang Z, Lu R et al (2022) Exposure to air pollution is associated with an increased risk of metabolic dysfunction-associated fatty liver disease. J Hepatol 76(3):518\u2013525. https:\/\/doi.org\/10.1016\/j.jhep.2021.10.016","journal-title":"J Hepatol"},{"issue":"2","key":"391_CR40","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jhep.2016.03.011","volume":"65","author":"E Tr\u00e9po","year":"2016","unstructured":"Tr\u00e9po E, Romeo S, Zucman-Rossi J, Nahon P (2016) PNPLA3 gene in liver diseases. J Hepatol 65(2):399\u2013412. https:\/\/doi.org\/10.1016\/j.jhep.2016.03.011","journal-title":"J Hepatol"},{"issue":"6","key":"391_CR41","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1002\/hep.24283","volume":"53","author":"S Sookoian","year":"2011","unstructured":"Sookoian S, Pirola CJ (2011) Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 53(6):1883\u20131894. https:\/\/doi.org\/10.1002\/hep.24283","journal-title":"Hepatology"},{"issue":"2","key":"391_CR42","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jhep.2017.09.003","volume":"68","author":"M Eslam","year":"2018","unstructured":"Eslam M, Valenti L, Romeo S (2018) Genetics and epigenetics of NAFLD and NASH: clinical impact. J Hepatol 68(2):268\u2013279. https:\/\/doi.org\/10.1016\/j.jhep.2017.09.003","journal-title":"J Hepatol"},{"key":"391_CR43","doi-asserted-by":"publisher","first-page":"2","DOI":"10.21037\/tgh.2019.09.06","volume":"6","author":"NS Choudhary","year":"2021","unstructured":"Choudhary NS, Duseja A (2021) Genetic and epigenetic disease modifiers: non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD). Transl Gastroenterol Hepatol 6:2. https:\/\/doi.org\/10.21037\/tgh.2019.09.06","journal-title":"Transl Gastroenterol Hepatol"},{"key":"391_CR44","doi-asserted-by":"publisher","first-page":"12757","DOI":"10.1038\/ncomms12757","volume":"7","author":"K Thabet","year":"2016","unstructured":"Thabet K, Asimakopoulos A, Shojaei M, Romero-Gomez M, Mangia A, Irving WL et al (2016) MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C. Nat Commun 7:12757. https:\/\/doi.org\/10.1038\/ncomms12757","journal-title":"Nat Commun"},{"issue":"6","key":"391_CR45","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1002\/hep.29064","volume":"65","author":"K Thabet","year":"2017","unstructured":"Thabet K, Chan HLY, Petta S, Mangia A, Berg T, Boonstra A et al (2017) The membrane-bound O-acyltransferase domain-containing 7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B. Hepatology 65(6):1840\u20131850. https:\/\/doi.org\/10.1002\/hep.29064","journal-title":"Hepatology"},{"issue":"1","key":"391_CR46","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/hep.28475","volume":"64","author":"M Eslam","year":"2016","unstructured":"Eslam M, Mangia A, Berg T, Chan HLY, Irving WL, Dore GJ et al (2016) Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes. Hepatology 64(1):34\u201346. https:\/\/doi.org\/10.1002\/hep.28475","journal-title":"Hepatology"},{"issue":"3","key":"391_CR47","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.jhep.2018.10.021","volume":"70","author":"M Metwally","year":"2019","unstructured":"Metwally M, Bayoumi A, Romero-Gomez M, Thabet K, John M, Adams LA et al (2019) A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3\u2019UTR. J Hepatol 70(3):494\u2013500. https:\/\/doi.org\/10.1016\/j.jhep.2018.10.021","journal-title":"J Hepatol"},{"key":"391_CR48","doi-asserted-by":"publisher","unstructured":"Bayoumi A, Elsayed A, Han S, Petta S, Adams LA, Aller R, et al. (2021) Mistranslation drives alterations in protein levels and the effects of a synonymous variant at the fibroblast growth factor 21 locus. Adv Sci 8(11). doi: https:\/\/doi.org\/10.1002\/advs.202004168","DOI":"10.1002\/advs.202004168"},{"key":"391_CR49","doi-asserted-by":"publisher","first-page":"6422","DOI":"10.1038\/ncomms7422","volume":"6","author":"M Eslam","year":"2015","unstructured":"Eslam M, Hashem AM, Leung R, Romero-Gomez M, Berg T, Dore GJ et al (2015) Interferon-\u03bb rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. Nat Commun 6:6422. https:\/\/doi.org\/10.1038\/ncomms7422","journal-title":"Nat Commun"},{"issue":"5","key":"391_CR50","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/ng.3836","volume":"49","author":"M Eslam","year":"2017","unstructured":"Eslam M, McLeod D, Kelaeng KS, Mangia A, Berg T, Thabet K et al (2017) IFN-\u03bb3, not IFN-\u03bb4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis. Nat Genet 49(5):795\u2013800. https:\/\/doi.org\/10.1038\/ng.3836","journal-title":"Nat Genet"},{"issue":"2","key":"391_CR51","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jhep.2015.11.008","volume":"64","author":"M Eslam","year":"2016","unstructured":"Eslam M, Hashem AM, Romero-Gomez M, Berg T, Dore GJ, Mangia A et al (2016) FibroGENE: a gene-based model for staging liver fibrosis. J Hepatol 64(2):390\u2013398. https:\/\/doi.org\/10.1016\/j.jhep.2015.11.008","journal-title":"J Hepatol"},{"key":"391_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103521","volume":"70","author":"M Metwally","year":"2021","unstructured":"Metwally M, Bayoumi A, Khan A, Adams LA, Aller R, Garc\u00eda-Monz\u00f3n C et al (2021) Copy number variation and expression of exportin-4 associates with severity of fibrosis in metabolic associated fatty liver disease. EBioMedicine 70:103521. https:\/\/doi.org\/10.1016\/j.ebiom.2021.103521","journal-title":"EBioMedicine"},{"issue":"2","key":"391_CR53","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1053\/j.gastro.2003.10.065","volume":"126","author":"HB El-Serag","year":"2004","unstructured":"El-Serag HB, Tran T, Everhart JE (2004) Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 126(2):460\u2013468. https:\/\/doi.org\/10.1053\/j.gastro.2003.10.065","journal-title":"Gastroenterology"},{"issue":"1","key":"391_CR54","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/MCG.0b013e3182a030c4","volume":"47","author":"J Raxitkumar","year":"2013","unstructured":"Raxitkumar J, Suhag P, Suthat L (2013) The association between metabolic syndrome and hepatocellular carcinoma: systemic review and meta-analysis. J Clin Gastroenterol 47(1):33\u201344. https:\/\/doi.org\/10.1097\/MCG.0b013e3182a030c4","journal-title":"J Clin Gastroenterol"},{"issue":"3","key":"391_CR55","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1002\/hep.22734","volume":"49","author":"V Paradis","year":"2009","unstructured":"Paradis V, Zalisnski S, Chelbi E, Guedj N, Degos F, Vilgrain V et al (2009) Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liverfibrosis: a pathological analysis. Hepatology 49(3):851\u2013859. https:\/\/doi.org\/10.1002\/hep.22734","journal-title":"Hepatology"},{"key":"391_CR56","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.blre.2016.02.002","volume":"30","author":"BE Paluch","year":"2016","unstructured":"Paluch BE, Naqash AR, Brumberger Z, Nemeth MJ, Griffiths EA (2016) Epigenetics: a primer for clinicians. Blood Rev 30:285\u2013295. https:\/\/doi.org\/10.1016\/j.blre.2016.02.002","journal-title":"Blood Rev"},{"issue":"1","key":"391_CR57","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1017\/S0954422411000199","volume":"25","author":"D Teegarden","year":"2021","unstructured":"Teegarden D, Romieu I, Leli\u00e8vre SA (2021) Redefining the impact of nutrition on breast cancer incidence: is epigenetics involved? Nutr Res Rev 25(1):68\u201395. https:\/\/doi.org\/10.1017\/S0954422411000199","journal-title":"Nutr Res Rev"},{"issue":"3","key":"391_CR58","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1053\/j.gastro.2015.07.011","volume":"176","author":"CM Lakhani","year":"2017","unstructured":"Lakhani CM, Tierney BT, Manrai AK, Yang J, Visscher PM, Patel CJ (2017) Epigenetic alterations in colorectal cancer: emerging biomarkers. Physiol Behav 176(3):139\u2013148. https:\/\/doi.org\/10.1053\/j.gastro.2015.07.011","journal-title":"Physiol Behav"},{"issue":"21","key":"391_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21218138","volume":"21","author":"J Hyun","year":"2020","unstructured":"Hyun J, Jung Y (2020) Dna methylation in nonalcoholic fatty liver disease. Int J Mol Sci 21(21):1\u201326. https:\/\/doi.org\/10.3390\/ijms21218138","journal-title":"Int J Mol Sci"},{"issue":"2","key":"391_CR60","doi-asserted-by":"publisher","first-page":"922","DOI":"10.3390\/nu7020922","volume":"7","author":"KS Bishop","year":"2015","unstructured":"Bishop KS, Ferguson LR (2015) The interaction between epigenetics, nutrition and the development of cancer. Nutrients 7(2):922\u2013947. https:\/\/doi.org\/10.3390\/nu7020922","journal-title":"Nutrients"},{"issue":"10","key":"391_CR61","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s00018-019-03390-0","volume":"176","author":"JK DiStefano","year":"2017","unstructured":"DiStefano JK (2017) Fructose-mediated effects on gene expression and epigenetic mechanisms associated with NAFLD pathogenesis. Physiol Behav 176(10):139\u2013148. https:\/\/doi.org\/10.1007\/s00018-019-03390-0","journal-title":"Physiol Behav"},{"issue":"2","key":"391_CR62","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1002\/jimd.12011","volume":"42","author":"SB Wortmann","year":"2019","unstructured":"Wortmann SB, Mayr JA (2019) Choline-related-inherited metabolic diseases\u2014a mini review. J Inherit Metab Dis 42(2):237\u2013242. https:\/\/doi.org\/10.1002\/jimd.12011","journal-title":"J Inherit Metab Dis"},{"issue":"3","key":"391_CR63","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.ymgme.2013.08.022","volume":"110","author":"P Cordero","year":"2013","unstructured":"Cordero P, Campion J, Milagro FI, Martinez JA (2013) Transcriptomic and epigenetic changes in early liver steatosis associated to obesity: effect of dietary methyl donor supplementation. Mol Genet Metab 110(3):388\u2013395. https:\/\/doi.org\/10.1016\/j.ymgme.2013.08.022","journal-title":"Mol Genet Metab"},{"issue":"1","key":"391_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13578-021-00701-6","volume":"11","author":"N Wu","year":"2021","unstructured":"Wu N, Yuan F, Yue S, Jiang F, Ren D, Liu L et al (2021) Effect of exercise and diet intervention in NAFLD and NASH via GAB2 methylation. Cell Biosci 11(1):1\u201314. https:\/\/doi.org\/10.1186\/s13578-021-00701-6","journal-title":"Cell Biosci"},{"key":"391_CR65","doi-asserted-by":"publisher","unstructured":"Qin Y, Li B, Arumugam S, Lu Q, Mankash SM, Li J, et al. (2021) m6A mRNA methylation-directed myeloid cell activation controls progression of NAFLD and obesity. Cell Rep. 37(6). https:\/\/doi.org\/10.1016\/j.celrep.2021.109968","DOI":"10.1016\/j.celrep.2021.109968"},{"issue":"1","key":"391_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13148-021-01129-y","volume":"13","author":"ND Johnson","year":"2021","unstructured":"Johnson ND, Wu X, Still CD, Chu X, Petrick AT, Gerhard GS et al (2021) Differential DNA methylation and changing cell-type proportions as fibrotic stage progresses in NAFLD. Clin Epigenetics 13(1):1\u201314. https:\/\/doi.org\/10.1186\/s13148-021-01129-y","journal-title":"Clin Epigenetics"},{"issue":"5","key":"391_CR67","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1093\/humupd\/dmz017","volume":"25","author":"MJ Xavier","year":"2019","unstructured":"Xavier MJ, Roman SD, Aitken RJ, Nixon B (2019) Transgenerational inheritance: how impacts to the epigenetic and genetic information of parents affect offspring health. Hum Reprod Update 25(5):519\u2013541. https:\/\/doi.org\/10.1093\/humupd\/dmz017","journal-title":"Hum Reprod Update"},{"key":"391_CR68","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/741465","author":"M Gori","year":"2014","unstructured":"Gori M, Arciello M, Balsano C (2014) MicroRNAs in nonalcoholic fatty liver disease: novel biomarkers and prognostic tools during the transition from steatosis to hepatocarcinoma. Biomed Res Int. https:\/\/doi.org\/10.1155\/2014\/741465","journal-title":"Biomed Res Int"},{"issue":"12","key":"391_CR69","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.2337\/db09-1003","volume":"58","author":"C Ling","year":"2009","unstructured":"Ling C, Groop L (2009) Epigenetics: a molecular link between environmental factors and type 2 diabetes. Diabetes 58(12):2718\u20132725. https:\/\/doi.org\/10.2337\/db09-1003","journal-title":"Diabetes"},{"issue":"8","key":"391_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells10081945","volume":"10","author":"X Zeng","year":"2021","unstructured":"Zeng X, Yuan X, Cai Q, Tang C, Gao J (2021) Circular rna as an epigenetic regulator in chronic liver diseases. Cells 10(8):1\u201315. https:\/\/doi.org\/10.3390\/cells10081945","journal-title":"Cells"},{"issue":"8","key":"391_CR71","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1517\/14728222.2012.703656","volume":"16","author":"VK Pulla","year":"2012","unstructured":"Pulla VK, Battu MB, Alvala M, Sriram D, Yogeeswari P (2012) Can targeting SIRT-1 to treat type 2 diabetes be a good strategy? A review Expert Opin Ther Targets 16(8):819\u2013832. https:\/\/doi.org\/10.1517\/14728222.2012.703656","journal-title":"A review Expert Opin Ther Targets"},{"issue":"7","key":"391_CR72","doi-asserted-by":"publisher","first-page":"852","DOI":"10.7150\/ijbs.19370","volume":"13","author":"RB Ding","year":"2017","unstructured":"Ding RB, Bao JL, Deng CX (2017) Emerging roles of SIRT1 in fatty liver diseases. Int J Biol Sci 13(7):852\u2013867. https:\/\/doi.org\/10.7150\/ijbs.19370","journal-title":"Int J Biol Sci"},{"issue":"44","key":"391_CR73","doi-asserted-by":"publisher","first-page":"33959","DOI":"10.1074\/jbc.M110.122978","volume":"285","author":"B Ponugoti","year":"2010","unstructured":"Ponugoti B, Kim DH, Xiao Z, Smith Z, Miao J, Zang M et al (2010) SIRT1 deacetylates and inhibits SREBP-IR 1C activity in regulation of hepatic lipid metabolism. J Biol Chem 285(44):33959\u201333970. https:\/\/doi.org\/10.1074\/jbc.M110.122978","journal-title":"J Biol Chem"},{"issue":"7","key":"391_CR74","doi-asserted-by":"publisher","first-page":"682","DOI":"10.7150\/ijbs.6.682","volume":"6","author":"RH Wang","year":"2010","unstructured":"Wang RH, Li C, Deng CX (2010) Liver steatosis and increased ChREBP expression in mice carrying a liver specific SIRT1 null mutation under a normal feeding condition. Int J Biol Sci 6(7):682\u2013690. https:\/\/doi.org\/10.7150\/ijbs.6.682","journal-title":"Int J Biol Sci"},{"issue":"5","key":"391_CR75","doi-asserted-by":"publisher","first-page":"5","DOI":"10.12659\/msm.881749","volume":"17","author":"Y Colak","year":"2011","unstructured":"Colak Y, Ozturk O, Senates E, Tuncer I, Yorulmaz E, Adali G et al (2011) SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease. Med Sci Monit 17(5):5\u20139. https:\/\/doi.org\/10.12659\/msm.881749","journal-title":"Med Sci Monit"},{"issue":"2","key":"391_CR76","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1371\/journal.pbio.0040031","volume":"4","author":"L Bordone","year":"2006","unstructured":"Bordone L, Motta MC, Picard F, Robinson A, Jhala US, Apfeld J et al (2006) Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic beta cells. PLoS Biol 4(2):210\u2013220. https:\/\/doi.org\/10.1371\/journal.pbio.0040031","journal-title":"PLoS Biol"},{"issue":"1","key":"391_CR77","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jdiacomp.2015.08.022","volume":"30","author":"Y Cao","year":"2016","unstructured":"Cao Y, Jiang X, Ma H, Wang Y, Xue P, Liu Y (2016) SIRT1 and insulin resistance. J Diabetes Complications 30(1):178\u2013183. https:\/\/doi.org\/10.1016\/j.jdiacomp.2015.08.022","journal-title":"J Diabetes Complications"},{"key":"391_CR78","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.736677","author":"M Vulf","year":"2021","unstructured":"Vulf M, Shunkina D, Komar A, Bograya M, Zatolokin P, Kirienkova E et al (2021) Analysis of miRNAs profiles in serum of patients with steatosis and steatohepatitis. Front Cell Dev Biol. https:\/\/doi.org\/10.3389\/fcell.2021.736677","journal-title":"Front Cell Dev Biol"},{"issue":"46","key":"391_CR79","doi-asserted-by":"publisher","first-page":"8140","DOI":"10.3748\/wjg.v23.i46.8140","volume":"23","author":"XL Liu","year":"2017","unstructured":"Liu XL, Cao HX, Wang BC, Xin FZ, Zhang RN, Zhou D et al (2017) miR-192-5p regulates lipid synthesis in non-alcoholic fatty liver disease through SCD-1. World J Gastroenterol 23(46):8140\u20138151. https:\/\/doi.org\/10.3748\/wjg.v23.i46.8140","journal-title":"World J Gastroenterol"},{"issue":"2","key":"391_CR80","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/hep.31050","volume":"72","author":"XL Liu","year":"2020","unstructured":"Liu XL, Pan Q, Cao HX, Xin FZ, Zhao ZH, Yang RX et al (2020) Lipotoxic hepatocyte-derived exosomal microRNA 192\u20135p activates macrophages through rictor\/Akt\/forkhead box transcription factor O1 signaling in nonalcoholic fatty liver disease. Hepatology 72(2):454\u2013469. https:\/\/doi.org\/10.1002\/hep.31050","journal-title":"Hepatology"},{"key":"391_CR81","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.614068","author":"FJ Ren","year":"2021","unstructured":"Ren FJ, Yao Y, Cai XY, Fang GY (2021) Emerging role of MiR-192-5p in human diseases. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2021.614068","journal-title":"Front Pharmacol"},{"issue":"1","key":"391_CR82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-26065-5","volume":"8","author":"AP Doumatey","year":"2018","unstructured":"Doumatey AP, He WJ, Gaye A, Lei L, Zhou J, Gibbons GH et al (2018) Circulating MiR-374a-5p is a potential modulator of the inflammatory process in obesity. Sci Rep 8(1):1\u20139. https:\/\/doi.org\/10.1038\/s41598-018-26065-5","journal-title":"Sci Rep"},{"issue":"6","key":"391_CR83","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/cmi.2018.7","volume":"15","author":"B Li","year":"2018","unstructured":"Li B, Selmi C, Tang R, Gershwin ME, Ma X (2018) The microbiome and autoimmunity: a paradigm from the gut\u2013liver axis. Cell Mol Immunol 15(6):595\u2013609. https:\/\/doi.org\/10.1038\/cmi.2018.7","journal-title":"Cell Mol Immunol"},{"issue":"9","key":"391_CR84","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.it.2018.05.002","volume":"39","author":"TE Adolph","year":"2018","unstructured":"Adolph TE, Grander C, Moschen AR, Tilg H (2018) Liver\u2013microbiome axis in health and disease. Trends Immunol 39(9):712\u2013723. https:\/\/doi.org\/10.1016\/j.it.2018.05.002","journal-title":"Trends Immunol"},{"issue":"12","key":"391_CR85","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.3390\/cells8121642","volume":"8","author":"S Parida","year":"2019","unstructured":"Parida S, Sharma D (2019) The microbiome-estrogen connection and breast cancer risk. Cells 8(12):1642. https:\/\/doi.org\/10.3390\/cells8121642","journal-title":"Cells"},{"issue":"2","key":"391_CR86","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1053\/jhep.2003.50048","volume":"37","author":"Z Li","year":"2003","unstructured":"Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB et al (2003) Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 37(2):343\u2013350. https:\/\/doi.org\/10.1053\/jhep.2003.50048","journal-title":"Hepatology"},{"issue":"7122","key":"391_CR87","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1038\/nature05414","volume":"444","author":"PJ Turnbaugh","year":"2006","unstructured":"Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI (2006) An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444(7122):1027\u20131031. https:\/\/doi.org\/10.1038\/nature05414","journal-title":"Nature"},{"issue":"3","key":"391_CR88","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jhep.2019.10.003","volume":"72","author":"A Albillos","year":"2020","unstructured":"Albillos A, de Gottardi A, Rescigno M (2020) The gut-liver axis in liver disease: pathophysiological basis for therapy. J Hepatol 72(3):558\u2013577. https:\/\/doi.org\/10.1016\/j.jhep.2019.10.003","journal-title":"J Hepatol"},{"issue":"11","key":"391_CR89","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.3390\/cells10112806","volume":"10","author":"R Xue","year":"2021","unstructured":"Xue R, Su L, Lai S, Wang Y, Zhao D, Fan J et al (2021) Bile acid receptors and the gut\u2013liver axis in nonalcoholic fatty liver disease. Cells 10(11):2806. https:\/\/doi.org\/10.3390\/cells10112806","journal-title":"Cells"},{"key":"391_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2020.100222","author":"G Grzych","year":"2021","unstructured":"Grzych G, Ch\u00e1vez-Talavera O, Descat A, Thuillier D, Verrijken A, Kouach M et al (2021) NASH-related increases in plasma bile acid levels depend on insulin resistance. JHEP Reports. https:\/\/doi.org\/10.1016\/j.jhepr.2020.100222","journal-title":"JHEP Reports"},{"issue":"2","key":"391_CR91","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/hep.29359","volume":"67","author":"P Puri","year":"2018","unstructured":"Puri P, Daita K, Joyce A, Mirshahi F, Santhekadur PK, Cazanave S et al (2018) The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids. Hepatology 67(2):534. https:\/\/doi.org\/10.1002\/hep.29359","journal-title":"Hepatology"},{"issue":"12","key":"391_CR92","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1136\/gutjnl-2012-303816","volume":"62","author":"T Le Roy","year":"2013","unstructured":"Le Roy T, Llopis M, Lepage P, Bruneau A, Rabot S, Bevilacqua C et al (2013) Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut 62(12):1787\u20131794. https:\/\/doi.org\/10.1136\/gutjnl-2012-303816","journal-title":"Gut"},{"issue":"3","key":"391_CR93","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1002\/hep.31417","volume":"73","author":"LJM Alferink","year":"2021","unstructured":"Alferink LJM, Radjabzadeh D, Erler NS, Vojinovic D, Medina-Gomez C, Uitterlinden AG et al (2021) Microbiomics, metabolomics, predicted metagenomics, and hepatic steatosis in a population-based study of 1,355 adults. Hepatology 73(3):968\u2013982. https:\/\/doi.org\/10.1002\/hep.31417","journal-title":"Hepatology"},{"issue":"2","key":"391_CR94","doi-asserted-by":"publisher","first-page":"227","DOI":"10.14218\/JCTH.2020.00131","volume":"9","author":"W Hern\u00e1ndez-Ceballos","year":"2021","unstructured":"Hern\u00e1ndez-Ceballos W, Cordova-Gallardo J, Mendez-Sanchez N (2021) Gut microbiota in metabolic-associated fatty liver disease and in other chronic metabolic diseases. J Clin Transl Hepatol 9(2):227\u2013238. https:\/\/doi.org\/10.14218\/JCTH.2020.00131","journal-title":"J Clin Transl Hepatol"},{"issue":"2","key":"391_CR95","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/hep.26093","volume":"57","author":"L Zhu","year":"2013","unstructured":"Zhu L, Baker SS, Gill C, Liu W, Alkhouri R, Baker RD et al (2013) Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 57(2):601\u2013609. https:\/\/doi.org\/10.1002\/hep.26093","journal-title":"Hepatology"},{"issue":"5","key":"391_CR96","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1053\/gast.2000.19267","volume":"119","author":"K Cope","year":"2000","unstructured":"Cope K, Risby T, Diehl AM (2000) Increased gastrointestinal ethanol production in obese mice: implications for fatty liver disease pathogenesis. Gastroenterology 119(5):1340\u20131347. https:\/\/doi.org\/10.1053\/gast.2000.19267","journal-title":"Gastroenterology"},{"key":"391_CR97","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1002\/hep.30908","volume":"4","author":"F Chen","year":"2020","unstructured":"Chen F, Esmaili S, Rogers GB, Bugianesi E, Petta S, Marchesini G et al (2020) Lean NAFLD: a distinct entity shaped by differential metabolic adaptation. Hepatology 4:1213\u20131227. https:\/\/doi.org\/10.1002\/hep.30908","journal-title":"Hepatology"},{"issue":"10","key":"391_CR98","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.3390\/nu12103100","volume":"12","author":"A P\u00e9rez-Montes de Oca","year":"2020","unstructured":"P\u00e9rez-Montes de Oca A, Juli\u00e1n MT, Ramos A, Puig-Domingo M, Alonso N (2020) Microbiota, Fiber, and NAFLD: is there any connection? Nutrients 12(10):3100. https:\/\/doi.org\/10.3390\/nu12103100","journal-title":"Nutrients"},{"issue":"5","key":"391_CR99","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1053\/j.gastro.2012.01.034.%0AA","volume":"142","author":"S Pendyala","year":"2012","unstructured":"Pendyala S, Walker JM, Holt PR (2012) A high-fat diet is associated with endotoxemia that originates from the gut. Gastroenterology 142(5):1\u20137. https:\/\/doi.org\/10.1053\/j.gastro.2012.01.034.%0AA","journal-title":"Gastroenterology"},{"key":"391_CR100","doi-asserted-by":"publisher","unstructured":"Oteng AB, Loregger A, van Weeghel M, Zelcer N, Kersten S. (2019) Industrial trans fatty acids stimulate SREBP2-mediated cholesterogenesis and promote non-alcoholic fatty liver disease. Mol Nutr Food Res. 63(19):1\u201316. oi: https:\/\/doi.org\/10.1002\/mnfr.201900385","DOI":"10.1002\/mnfr.201900385"},{"issue":"10","key":"391_CR101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11745-012-3709-7","volume":"47","author":"BA Neuschwander-Tetri","year":"2012","unstructured":"Neuschwander-Tetri BA, Ford DA, Acharya S, Gilkey G, Basaranoglu M, Tetri LH et al (2012) Dietary trans-fatty acid induced NASH is normalized following loss. Lipids 47(10):1\u20137. https:\/\/doi.org\/10.1007\/s11745-012-3709-7","journal-title":"Lipids"},{"issue":"2","key":"391_CR102","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3390\/nu9020096","volume":"9","author":"Q Chen","year":"2017","unstructured":"Chen Q, Wang T, Li J, Wang S, Qiu F, Yu H et al (2017) Effects of natural products on fructose-induced nonalcoholic fatty liver disease (NAFLD). Nutrients 9(2):96. https:\/\/doi.org\/10.3390\/nu9020096","journal-title":"Nutrients"},{"issue":"9","key":"391_CR103","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/nu9090981","volume":"9","author":"KW Ter Horst","year":"2017","unstructured":"Ter Horst KW, Serlie MJ (2017) Fructose consumption, lipogenesis, and non-alcoholic fatty liver disease. Nutrients 9(9):1\u201320. https:\/\/doi.org\/10.3390\/nu9090981","journal-title":"Nutrients"},{"issue":"3","key":"391_CR104","doi-asserted-by":"publisher","first-page":"285","DOI":"10.4093\/dmj.2020.0250","volume":"45","author":"AMY Zhang","year":"2021","unstructured":"Zhang AMY, Wellberg EA, Kopp JL, Johnson JD (2021) Hyperinsulinemia in obesity, inflammation, and cancer. Diabetes Metab J 45(3):285\u2013311. https:\/\/doi.org\/10.4093\/dmj.2020.0250","journal-title":"Diabetes Metab J"},{"issue":"3 SUPPL.","key":"391_CR105","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2337\/diab.45.3.s45","volume":"45","author":"RW Stout","year":"1996","unstructured":"Stout RW (1996) Hyperinsulinemia and atherosclerosis. Diabetes 45(3 SUPPL.):45\u201346. https:\/\/doi.org\/10.2337\/diab.45.3.s45","journal-title":"Diabetes"},{"issue":"2","key":"391_CR106","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s13679-017-0261-z","volume":"6","author":"KA Erion","year":"2017","unstructured":"Erion KA, Corkey BE (2017) Hyperinsulinemia: a cause of obesity? Curr Obes Rep 6(2):178\u2013186","journal-title":"Curr Obes Rep"},{"issue":"3","key":"391_CR107","doi-asserted-by":"publisher","first-page":"R173","DOI":"10.1007\/s13679-017-0261-z","volume":"232","author":"NM Templeman","year":"2017","unstructured":"Templeman NM, Skovs\u00f8 S, Page MM, Lim GE, Johnson JD (2017) A causal role for hyperinsulinemia in obesity. J Endocrinol 232(3):R173\u2013R183. https:\/\/doi.org\/10.1007\/s13679-017-0261-z","journal-title":"J Endocrinol"},{"issue":"8","key":"391_CR108","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms22084156","volume":"22","author":"Y Sakurai","year":"2021","unstructured":"Sakurai Y, Kubota N, Yamauchi T, Kadowaki T (2021) Role of insulin resistance in mafld. Int J Mol 22(8):1\u201326. https:\/\/doi.org\/10.3390\/ijms22084156","journal-title":"Int J Mol"},{"issue":"3","key":"391_CR109","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2337\/diaspect.17.3.183","volume":"17","author":"SL Aronoff","year":"2004","unstructured":"Aronoff SL, Berkowitz K, Shreiner B, Want L (2004) Glucose metabolism and regulation: beyond insulin and glucagon. Diabetes Spectr 17(3):183\u2013190. https:\/\/doi.org\/10.2337\/diaspect.17.3.183","journal-title":"Diabetes Spectr"},{"issue":"4","key":"391_CR110","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.cmet.2007.03.006","volume":"5","author":"S Huang","year":"2007","unstructured":"Huang S, Czech MP (2007) The GLUT4 glucose transporter. Cell Metab 5(4):237\u2013252. https:\/\/doi.org\/10.1016\/j.cmet.2007.03.006","journal-title":"Cell Metab"},{"issue":"46","key":"391_CR111","doi-asserted-by":"publisher","first-page":"6771","DOI":"10.3748\/wjg.v18.i46.6771","volume":"18","author":"S Karim","year":"2012","unstructured":"Karim S, Adams DH, Lalor PF (2012) Hepatic expression and cellular distribution of the glucose transporter family. World J Gastroenterol 18(46):6771\u20136781. https:\/\/doi.org\/10.3748\/wjg.v18.i46.6771","journal-title":"World J Gastroenterol"},{"issue":"4","key":"391_CR112","doi-asserted-by":"publisher","first-page":"333","DOI":"10.4196\/kjpp.2014.18.4.333","volume":"18","author":"GS Roh","year":"2014","unstructured":"Roh GS, Kim S, Jung J, Kim H, Heo RW, Yi CO et al (2014) Exendin-4 improves nonalcoholic fatty liver disease by regulating glucose transporter 4 expression in ob\/ob mice. Korean J Physiol Pharmacol 18(4):333\u2013339. https:\/\/doi.org\/10.4196\/kjpp.2014.18.4.333","journal-title":"Korean J Physiol Pharmacol"},{"issue":"33","key":"391_CR113","doi-asserted-by":"publisher","first-page":"4137","DOI":"10.3748\/wjg.15.4137","volume":"15","author":"S Kawahito","year":"2009","unstructured":"Kawahito S, Kitahata H, Oshita S (2009) Problems associated with glucose toxicity: role of hyperglycemia-induced oxidative stress. World J Gastroenterol 15(33):4137. https:\/\/doi.org\/10.3748\/wjg.15.4137","journal-title":"World J Gastroenterol"},{"issue":"1","key":"391_CR114","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.metabol.2014.10.012","volume":"64","author":"SA Polyzos","year":"2015","unstructured":"Polyzos SA, Kountouras J, Mantzoros CS (2015) Leptin in nonalcoholic fatty liver disease: a narrative review. Metabolism 64(1):60\u201378. https:\/\/doi.org\/10.1016\/j.metabol.2014.10.012","journal-title":"Metabolism"},{"issue":"4","key":"391_CR115","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/j.1478-3231.2007.01483.x","volume":"27","author":"N M\u00e9ndez-S\u00e1nchez","year":"2007","unstructured":"M\u00e9ndez-S\u00e1nchez N, Arrese M, Zamora-Vald\u00e9s D, Uribe M (2007) Current concepts in the pathogenesis of nonalcoholic fatty liver disease. Liver Int 27(4):423\u2013433. https:\/\/doi.org\/10.1111\/j.1478-3231.2007.01483.x","journal-title":"Liver Int"},{"issue":"5","key":"391_CR116","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1210\/er.2019-00034","volume":"40","author":"MJ Watt","year":"2019","unstructured":"Watt MJ, Miotto PM, De Nardo W, Montgomery MK (2019) The liver as an endocrine organ - linking NAFLD and insulin resistance. Endocr Rev 40(5):1367\u20131393. https:\/\/doi.org\/10.1210\/er.2019-00034","journal-title":"Endocr Rev"},{"issue":"5","key":"391_CR117","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1053\/j.gastro.2008.01.075","volume":"134","author":"KM Korenblat","year":"2008","unstructured":"Korenblat KM, Fabbrini E, Mohammed BS, Klein S (2008) Liver, muscle and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology 134(5):1369\u20131375. https:\/\/doi.org\/10.1053\/j.gastro.2008.01.075","journal-title":"Gastroenterology"},{"issue":"3","key":"391_CR118","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1172\/JCI134165","volume":"130","author":"GI Smith","year":"2020","unstructured":"Smith GI, Shankaran M, Yoshino M, Schweitzer GG, Chondronikola M, Beals JW et al (2020) Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease. J Clin Invest 130(3):1453\u20131460. https:\/\/doi.org\/10.1172\/JCI134165","journal-title":"J Clin Invest"},{"issue":"1","key":"391_CR119","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/cphy.c170012","volume":"8","author":"M Alves-Bezerra","year":"2018","unstructured":"Alves-Bezerra M, Cohen DE (2018) Triglyceride metabolism in the liver. Compr Physiol 8(1):1\u201322. https:\/\/doi.org\/10.1002\/cphy.c170012","journal-title":"Compr Physiol"},{"issue":"6","key":"391_CR120","doi-asserted-by":"publisher","first-page":"573","DOI":"10.2174\/18753183-v12-e2204040","volume":"18","author":"E Wasfy","year":"2018","unstructured":"Wasfy E, Elkassas G, Elnawasany S, Elkasrawy K, Abd-Elsalam S, Soliman S et al (2018) Predicting esophageal varices in cirrhotic hepatitis c virus patients using noninvasive measurement of insulin resistance variables. Endocrine, Metab Immune Disord - Drug Targets 18(6):573\u2013580. https:\/\/doi.org\/10.2174\/18753183-v12-e2204040","journal-title":"Endocrine, Metab Immune Disord - Drug Targets"},{"issue":"6","key":"391_CR121","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.metabol.2010.08.005","volume":"60","author":"S Ryu","year":"2011","unstructured":"Ryu S, Chang Y, Kim SG, Cho J, Guallar E (2011) Serum uric acid levels predict incident nonalcoholic fatty liver disease in healthy Korean men. Metabolism 60(6):860\u2013866. https:\/\/doi.org\/10.1016\/j.metabol.2010.08.005","journal-title":"Metabolism"},{"issue":"2","key":"391_CR122","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1515\/CCLM.2010.037","volume":"48","author":"YJ Lee","year":"2010","unstructured":"Lee YJ, Lee HR, Lee JH, Shin YH, Shim JY (2010) Association between serum uric acid and non-alcoholic fatty liver disease in Korean adults. Clin Chem Lab Med 48(2):175\u2013180. https:\/\/doi.org\/10.1515\/CCLM.2010.037","journal-title":"Clin Chem Lab Med"},{"issue":"8","key":"391_CR123","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1253\/circj.69.928","volume":"69","author":"WY Tae","year":"2005","unstructured":"Tae WY, Ki CS, Hun SS, Byung JK, Bum SK, Jin HK et al (2005) Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. Circ J 69(8):928\u2013933. https:\/\/doi.org\/10.1253\/circj.69.928","journal-title":"Circ J"},{"issue":"48","key":"391_CR124","doi-asserted-by":"publisher","first-page":"40732","DOI":"10.1074\/jbc.M112.399899","volume":"287","author":"MA Lanaspa","year":"2012","unstructured":"Lanaspa MA, Sanchez-Lozada LG, Choi YJ, Cicerchi C, Kanbay M, Roncal-Jimenez CA et al (2012) Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in fructose-dependent and -independent fatty liver. J Biol Chem 287(48):40732\u201340744. https:\/\/doi.org\/10.1074\/jbc.M112.399899","journal-title":"J Biol Chem"},{"issue":"5","key":"391_CR125","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.jhep.2018.01.019","volume":"68","author":"T Jensen","year":"2018","unstructured":"Jensen T, Abdelmalek MF, Sullivan S, Nadeau KJ, Green M, Roncal C et al (2018) Fructose and sugar: a major mediator of nonalcoholic fatty liver disease. J Hepatol 68(5):1063\u20131075. https:\/\/doi.org\/10.1016\/j.jhep.2018.01.019","journal-title":"J Hepatol"},{"issue":"6","key":"391_CR126","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1172\/JCI42344","volume":"120","author":"A So","year":"2010","unstructured":"So A, Thorens B (2010) Uric acid transport and disease. J Clin Invest 120(6):1791\u20131799. https:\/\/doi.org\/10.1172\/JCI42344","journal-title":"J Clin Invest"},{"issue":"2","key":"391_CR127","doi-asserted-by":"publisher","first-page":"136","DOI":"10.7717\/peerj.7563","volume":"49","author":"G Darmawan","year":"2017","unstructured":"Darmawan G, Hamijoyo L, Hasan I (2017) Association between serum uric acid and non-alcoholic fatty liver disease: a meta-analysis. Acta Med Indones 49(2):136\u2013147. https:\/\/doi.org\/10.7717\/peerj.7563","journal-title":"Acta Med Indones"},{"issue":"2","key":"391_CR128","doi-asserted-by":"publisher","first-page":"334","DOI":"10.6133\/apjcn.092016.04","volume":"26","author":"F Huang","year":"2017","unstructured":"Huang F, Liu A, Fang H, Geng X (2017) Serum uric acid levels in non-alcoholic steatosis patients: a meta-analysis. Asia Pac J Clin Nutr 26(2):334\u2013342. https:\/\/doi.org\/10.6133\/apjcn.092016.04","journal-title":"Asia Pac J Clin Nutr"},{"issue":"1","key":"391_CR129","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mito.2005.10.004","volume":"6","author":"K Begriche","year":"2006","unstructured":"Begriche K, Igoudjil A, Pessayre D, Fromenty B (2006) Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 6(1):1\u201328. https:\/\/doi.org\/10.1016\/j.mito.2005.10.004","journal-title":"Mitochondrion"},{"issue":"4","key":"391_CR130","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.jhep.2012.11.035","volume":"58","author":"S Chatterjee","year":"2013","unstructured":"Chatterjee S, Ganini D, Tokar EJ, Kumar A, Das S, Corbett J et al (2013) Leptin is key to peroxynitrite-mediated oxidative stress and Kupffer cell activation in experimental nonalcoholic steatohepatitis. J Hepatol 58(4):778. https:\/\/doi.org\/10.1016\/j.jhep.2012.11.035","journal-title":"J Hepatol"},{"issue":"4","key":"391_CR131","doi-asserted-by":"publisher","first-page":"6184","DOI":"10.3390\/ijms15046184","volume":"15","author":"UJ Jung","year":"2014","unstructured":"Jung UJ, Choi MS (2014) Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci 15(4):6184\u20136223. https:\/\/doi.org\/10.3390\/ijms15046184","journal-title":"Int J Mol Sci"},{"issue":"21","key":"391_CR132","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21218308","volume":"21","author":"ML Chang","year":"2020","unstructured":"Chang ML, Yang Z, Yang SS (2020) Roles of adipokines in digestive diseases: markers of inflammation, metabolic alteration and disease progression. Int J Mol Sci 21(21):1\u201336. https:\/\/doi.org\/10.3390\/ijms21218308","journal-title":"Int J Mol Sci"},{"issue":"1","key":"391_CR133","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.cmet.2013.05.010","volume":"18","author":"M Dalamaga","year":"2013","unstructured":"Dalamaga M, Chou SH, Shields K, Papageorgiou P, Polyzos SA, Mantzoros CS (2013) Leptin at the intersection of neuroendocrinology and metabolism: current evidence and therapeutic perspectives. Cell Metab 18(1):29\u201342. https:\/\/doi.org\/10.1016\/j.cmet.2013.05.010","journal-title":"Cell Metab"},{"issue":"1","key":"391_CR134","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s00125-015-3769-3","volume":"59","author":"SA Polyzos","year":"2016","unstructured":"Polyzos SA, Aronis KN, Kountouras J, Raptis DD, Vasiloglou MF, Mantzoros CS (2016) Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Diabetologia 59(1):30\u201343. https:\/\/doi.org\/10.1007\/s00125-015-3769-3","journal-title":"Diabetologia"},{"issue":"1","key":"391_CR135","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3803\/EnM.2018.33.1.33","volume":"33","author":"C Boutari","year":"2018","unstructured":"Boutari C, Perakakis N, Mantzoros CS (2018) Association of adipokines with development and progression of nonalcoholic fatty liver disease. Endocrinol Metab 33(1):33\u201343. https:\/\/doi.org\/10.3803\/EnM.2018.33.1.33","journal-title":"Endocrinol Metab"},{"issue":"42","key":"391_CR136","doi-asserted-by":"publisher","first-page":"43684","DOI":"10.1074\/jbc.M408495200","volume":"279","author":"C Duan","year":"2004","unstructured":"Duan C, Li M, Rui L (2004) SH2-B promotes insulin receptor substrate 1 (IRS1)- and IRS2-mediated activation of the phosphatidylinositol 3-kinase pathway in response to leptin. J Biol Chem 279(42):43684\u201343691. https:\/\/doi.org\/10.1074\/jbc.M408495200","journal-title":"J Biol Chem"},{"issue":"24","key":"391_CR137","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21249368","volume":"21","author":"M Mart\u00ednez-U\u00f1a","year":"2020","unstructured":"Mart\u00ednez-U\u00f1a M, L\u00f3pez-Manche\u00f1o Y, Di\u00e9guez C, Fern\u00e1ndez-Rojo MA, Novelle MG (2020) Unraveling the role of leptin in liver function and its relationship with liver diseases. Int J Mol Sci 21(24):1\u201333. https:\/\/doi.org\/10.3390\/ijms21249368","journal-title":"Int J Mol Sci"},{"issue":"3","key":"391_CR138","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1210\/er.2012-1053","volume":"34","author":"HS Moon","year":"2013","unstructured":"Moon HS, Dalamaga M, Kim SY, Polyzos SA, Hamnvik OP, Magkos F et al (2013) Leptin\u2019s role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals. Endocr Rev 34(3):377\u2013412. https:\/\/doi.org\/10.1210\/er.2012-1053","journal-title":"Endocr Rev"},{"issue":"6","key":"391_CR139","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1002\/hep.20965","volume":"42","author":"S Aleffi","year":"2005","unstructured":"Aleffi S, Petrai I, Bertolani C, Parola M, Colombatto S, Novo E et al (2005) Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology 42(6):1339\u20131348. https:\/\/doi.org\/10.1002\/hep.20965","journal-title":"Hepatology"},{"issue":"1","key":"391_CR140","doi-asserted-by":"publisher","first-page":"10","DOI":"10.2119\/molmed.2011.00243","volume":"18","author":"K Yan","year":"2012","unstructured":"Yan K, Deng X, Zhai X, Zhou M, Jia X, Luo L et al (2012) p38 Mitogen-activated protein kinase and liver X receptor-\u03b1 mediate the leptin effect on sterol regulatory element binding protein-1c expression in hepatic stellate cells. Mol Med 18(1):10. https:\/\/doi.org\/10.2119\/molmed.2011.00243","journal-title":"Mol Med"},{"issue":"5","key":"391_CR141","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1053\/gast.2002.32995","volume":"122","author":"K Ikejima","year":"2002","unstructured":"Ikejima K, Takei Y, Honda H, Hirose M, Yoshikawa M, Zhang YJ et al (2002) Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology 122(5):1399\u20131410. https:\/\/doi.org\/10.1053\/gast.2002.32995","journal-title":"Gastroenterology"},{"issue":"1","key":"391_CR142","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.cmet.2012.05.012","volume":"16","author":"K Imajo","year":"2012","unstructured":"Imajo K, Fujita K, Yoneda M, Nozaki Y, Ogawa Y, Shinohara Y et al (2012) Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis is regulated by leptin-mediated signaling. Cell Metab 16(1):44\u201354. https:\/\/doi.org\/10.1016\/j.cmet.2012.05.012","journal-title":"Cell Metab"},{"issue":"2","key":"391_CR143","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/s0168-8278(02)00102-2","volume":"37","author":"IA Leclercq","year":"2002","unstructured":"Leclercq IA, Farrell GC, Schriemer R, Robertson GR (2002) Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol 37(2):206\u2013213. https:\/\/doi.org\/10.1016\/s0168-8278(02)00102-2","journal-title":"J Hepatol"},{"issue":"8","key":"391_CR144","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1590\/0004-2730000003174","volume":"58","author":"AJ Rodr\u00edguez","year":"2014","unstructured":"Rodr\u00edguez AJ, Neeman T, Giles AG, Mastronardi CA, Paz-Filho G (2014) Leptin replacement therapy for the treatment of non-HAART associated lipodystrophy syndromes: a meta-analysis into the effects of leptin on metabolic and hepatic endpoints. Arq Bras Endocrinol 58(8):783\u2013797. https:\/\/doi.org\/10.1590\/0004-2730000003174","journal-title":"Arq Bras Endocrinol"},{"key":"391_CR145","doi-asserted-by":"publisher","unstructured":"Paz-Filho G, Mastronardi C, Wong M-L, Licinio J. (2012) Leptin therapy, insulin sensitivity, and glucose homeostasis. Indian J Endocrinol Metab 16(Suppl 3):S549. oi: https:\/\/doi.org\/10.4103\/2230-8210.105571","DOI":"10.4103\/2230-8210.105571"},{"issue":"3","key":"391_CR146","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s12020-018-1589-1","volume":"60","author":"RJ Brown","year":"2018","unstructured":"Brown RJ, Oral EA, Cochran E et al (2018) Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy. Endocrine 60(3):479\u2013489. https:\/\/doi.org\/10.1007\/s12020-018-1589-1","journal-title":"Endocrine"},{"key":"391_CR147","doi-asserted-by":"publisher","unstructured":"Akinci B, Subauste A, Ajluni N, et al. (2021) Metreleptin therapy for nonalcoholic steatohepatitis: open-label therapy interventions in two different clinical settings; 2(7):814\u2013835. doi:https:\/\/doi.org\/10.1016\/j.medj.2021.04.001","DOI":"10.1016\/j.medj.2021.04.001"},{"issue":"9","key":"391_CR148","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1515\/BC.2010.104","volume":"391","author":"JT Heiker","year":"2010","unstructured":"Heiker JT, Kosel D, Beck-Sickinger AG (2010) Molecular mechanisms of signal transduction via adiponectin and adiponectin receptors. Biol Chem 391(9):1005\u20131018. https:\/\/doi.org\/10.1515\/BC.2010.104","journal-title":"Biol Chem"},{"issue":"1","key":"391_CR149","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/hep.20280","volume":"40","author":"JM Hui","year":"2004","unstructured":"Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J (2004) Beyond insulin resistance in NASH: TNF-\u03b1 or adiponectin? Hepatology 40(1):46\u201354. https:\/\/doi.org\/10.1002\/hep.20280","journal-title":"Hepatology"},{"issue":"10","key":"391_CR150","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1111\/1751-2980.12288","volume":"16","author":"YJ Zhou","year":"2015","unstructured":"Zhou YJ, Zhang ZS, Nie YQ, Cao J, Cao CY, Li YY (2015) Association of adiponectin gene variation with progression of nonalcoholic fatty liver disease: a 4-year follow-up survey. J Dig Dis 16(10):601\u2013609. https:\/\/doi.org\/10.1111\/1751-2980.12288","journal-title":"J Dig Dis"},{"issue":"3","key":"391_CR151","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.metabol.2010.09.003","volume":"60","author":"SA Polyzos","year":"2011","unstructured":"Polyzos SA, Toulis KA, Goulis DG, Zavos C, Kountouras J (2011) Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism 60(3):313\u2013326. https:\/\/doi.org\/10.1016\/j.metabol.2010.09.003","journal-title":"Metabolism"},{"key":"391_CR152","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.572490","volume":"11","author":"TS Della","year":"2020","unstructured":"Della TS (2020) Non-alcoholic fatty liver disease as a canonical example of metabolic inflammatory-based liver disease showing a sex-specific prevalence: relevance of estrogen signaling. Front Endocrinol (Lausanne) 11:572490. https:\/\/doi.org\/10.3389\/fendo.2020.572490","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"23","key":"391_CR153","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1056\/NEJM199906103402306","volume":"340","author":"ME Mendelsohn","year":"2010","unstructured":"Mendelsohn ME, Karas RH (2010) The protective effects of estrogen on the cardiovascular system. Mech Dis 340(23):1801\u20131811. https:\/\/doi.org\/10.1056\/NEJM199906103402306","journal-title":"Mech Dis"},{"issue":"4","key":"391_CR154","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/S1665-2681(19)31616-3","volume":"9","author":"Y Gutierrez-Grobe","year":"2010","unstructured":"Gutierrez-Grobe Y, Ponciano-Rodr\u00edguez G, Ramos MH, Uribe M, M\u00e9ndez-S\u00e1nchez N (2010) Prevalence of non alcoholic fatty liver disease in premenopausal, posmenopausal and polycystic ovary syndrome women The role of estrogens. Ann Hepatol 9(4):402\u2013409. https:\/\/doi.org\/10.1016\/S1665-2681(19)31616-3","journal-title":"Ann Hepatol"},{"issue":"43","key":"391_CR155","doi-asserted-by":"publisher","first-page":"35983","DOI":"10.1074\/jbc.M507339200","volume":"280","author":"TM D\u2019Eon","year":"2005","unstructured":"D\u2019Eon TM, Souza SC, Aronovitz M, Obin MS, Fried SK, Greenberg AS (2005) Estrogen regulation of adiposity and fuel partitioning: evidence of genomic and non-genomic regulation of lipogenic and oxidative pathways. J Biol Chem 280(43):35983\u201335991. https:\/\/doi.org\/10.1074\/jbc.M507339200","journal-title":"J Biol Chem"},{"key":"391_CR156","doi-asserted-by":"publisher","unstructured":"Paquette A, Shinoda M, Lhoret RR, Prud\u2019homme D, Lavoie JM. (2007) Time course of liver lipid infiltration in ovariectomized rats: impact of a high-fat diet. 58(2):182\u201390. doi: https:\/\/doi.org\/10.1016\/j.maturitas.2007.08.002","DOI":"10.1016\/j.maturitas.2007.08.002"},{"issue":"7497","key":"391_CR157","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1136\/bmj.38391.663287.E0","volume":"330","author":"S Bruno","year":"2005","unstructured":"Bruno S, Maisonneuve P, Castellana P, Rotmensz N, Rossi S, Maggioni M et al (2005) Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. BMJ 330(7497):932. https:\/\/doi.org\/10.1136\/bmj.38391.663287.E0","journal-title":"BMJ"}],"updated-by":[{"DOI":"10.1007\/s42000-022-00395-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T00:00:00Z","timestamp":1661731200000}}],"container-title":["Hormones"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-022-00391-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s42000-022-00391-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-022-00391-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T01:27:59Z","timestamp":1669858079000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s42000-022-00391-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,3]]},"references-count":157,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["391"],"URL":"https:\/\/doi.org\/10.1007\/s42000-022-00391-w","relation":{},"ISSN":["1109-3099","2520-8721"],"issn-type":[{"value":"1109-3099","type":"print"},{"value":"2520-8721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,3]]},"assertion":[{"value":"4 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s42000-022-00395-6","URL":"https:\/\/doi.org\/10.1007\/s42000-022-00395-6","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}